SLC5A2 and hydrops fetalis: This is consistent with ESC 2021 HF guidelines (reinforced by the 2023 focused update) and the ACC/AHA/HFSA 2022 HF guidelines, which position SGLT2 inhibitors as a component of foundational pharmacotherapy for HFrEF regardless of glycemic status [19].